Primovist™ (U.S brand name Eovist®) is a highly specific MRI contrast agent for the imaging, detection and characterization of liver conditions, including liver tumors, cysts, as well as other malignant and benign lesions. It is a water-soluble ethoxybenzyl derivative of Gd-DTPA. This compound is taken up by the hepatocytes (approximately 30% of the dose goes to the hepatocytes) and is equally excreted renal and biliary in humans.
Primovist™ brightens the signal of T1 weighted MR images immediately after contrast administration. Dynamic scanning and imaging of the accumulation phase (best after 20 min.) can also be performed after bolus injection of Primovistâ„¢. The hepatocytes uptake will increase the signal intensity of normal liver parenchyma. This results in improved lesion-to-liver contrast because malignant tumors (metastases, the majority of hepatocellular carcinomas) do not contain either hepatocytes or their functioning is hampered.

WARNING: Gadolinium-based contrast agents increase the risk for nephrogenic systemic fibrosis (NSF) in patients with acute or chronic severe renal insufficiency (glomerular filtration rate less than 30 mL/min/1.73m²), or acute renal insufficiency of any severity due to the hepato-renal syndrome or in the perioperative liver transplantation period.

Refocused GRE sequences use a refocusing gradient in the phase encoding direction during the end module to maximize (refocus) remaining xy- (transverse) magnetization at the time when the next excitation is due, while the other two gradients are, in any case, balanced.
When the next excitation pulse is sent into the system with an opposed phase, it tilts the magnetization in the α direction. As a result the z-magnetization is again partly tilted into the xy-plane, while the remaining xy-magnetization is tilted partly into the z-direction.
Companies use different acronyms to describe certain techniques.

Different terms for these gradient echo pulse sequences
R-GRE Refocused Gradient Echo,
FAST Fourier Acquired Steady State,
FFE Fast Field echo,
FISP Fast Imaging with Steady State Precession,
F-SHORT SHORT Repetition Technique Based on Free Induction Decay,
GFEC Gradient Field Echo with Contrast,
GRASS Gradient Recalled Acquisition in Steady State,
ROAST Resonant Offset Averaging in the Steady State,
SSFP Steady State Free Precession.
STERF Steady State Technique with Refocused FID
In this context, 'contrast' refers to the pulse sequence, it does not mean enhancement with a contrast agent.

Resovist® is an organ-specific MRI contrast agent, used for the detection and characterization of especially small focal liver lesions.
Resovist® consists of superparamagnetic iron oxide (SPIO) nanoparticles coated with carboxydextran, which are accumulated by phagocytosis in cells of the reticuloendothelial system (RES) of the liver. The uptake of Resovist® Injection in the reticuloendothelial cells results in a decrease of the signal intensity of normal liver parenchyma on both T2- and T1 weighted images.
Most malignant liver tumors do not contain RES cells and therefore do not uptake the iron particles. The resulting imaging effect is an improved contrast between the tumor (bright) and the surrounding tissue (dark).
Resovist® can be injected as an intravenous bolus, which allows immediate imaging of the liver and reduces the overall examination time. A dynamic imaging strategy after bolus injection supports to characterize lesions. In comprehensive clinical trials, it demonstrated an excellent safety profile.
In 2001, Resovist® was approved for the European market.

See also Superparamagnetic Iron Oxide.

Resovist® competed with Primovist™, the other liver imaging agent of Bayer Schering Pharma AG. Due to this reason, the production of Resovist® has been abandoned in 2009.

The spins flow with the blood through a slice and experience a RF pulse. If they flow out of the slice by the time the signal is recorded (because the repetition time (TR) is asynchronous with the pulsatile flow), the flowing blood produces intravascular signal void by 'time of flight' effects, turbulent dephasing and first echo dephasing. The liquid flow occasionally produces an intravascular high signal intensity due to flow related enhancement, even echo rephasing and diastolic pseudogating.

See also Flow Artifact and Flow Effects.

Spoiled gradient echo sequences use a spoiler gradient on the slice select axis during the end module to destroy any remaining transverse magnetization after the readout gradient, which is the case for short repetition times.
As a result, only z-magnetization remains during a subsequent excitation. This types of sequences use semi-random changes in the phase of radio frequency pulses to produce a spatially independent phase shift.
Companies use different acronyms to describe certain techniques.

Different terms for these gradient echo pulse sequences:
CE-FFE-T1 Contrast Enhanced Fast Field Echo with T1 Weighting,
GFE Gradient Field Echo,
FLASH Fast Low Angle Shot,
PS Partial Saturation,
RF spoiled FAST RF Spoiled Fourier Acquired Steady State Technique,
RSSARGE Radio Frequency Spoiled Steady State Acquisition Rewound Gradient Echo
S-GRE Spoiled Gradient Echo,
SHORT Short Repetition Techniques,
SPGR Spoiled Gradient Recalled (spoiled GRASS),
STAGE T1W T1 weighted Small Tip Angle Gradient Echo,
T1-FAST T1 weighted Fourier Acquired Steady State Technique,
T1-FFE T1 weighted Fast Field Echo.
In this context, 'contrast enhanced' refers to the pulse sequence, it does not mean enhancement with a contrast agent.